Ttvax Llc 1

1. The role of major allergens Art v 1 and Art v 3 in Artemisia pollen-induced asthma: a mouse model study
2. A recombinant Artemisia vulgaris pollen adjuvanted Art v 1 protein-based vaccine treats allergic rhinitis and bronchial asthma using pre- and co-seasonal ultrashort immunotherapy regimens in sensitized mice
3. Evaluation of a SARS-CoV-2 spike protein ectodomain subunit vaccine with a squalene emulsion adjuvant in rodents and rhesus macaques
4. A Spike Protein-Based Subunit SARS-CoV-2 Vaccine for Pets: Safety, Immunogenicity, and Protective Efficacy in Juvenile Cats
5. An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters
6. Author Correction: An intranasal vaccine comprising SARS‑CoV‑2 spike receptor‑binding domain protein entrapped in mannose‑conjugated chitosan nanoparticle provides protection in hamsters (Scientific Reports, (2023), 13, 1, (12115), 10.1038/s41598-023-39402-0)
7. Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy of Artemisia Pollen-Induced Allergic Bronchial Asthma in a Mouse Model
8. Evaluation of commercial vaccines for efficacy and transmission control against the emergent H5N8 (clade 2.3.4.4b) avian influenza virus in Kazakhstan
9. Evaluation of safety, immunogenicity, and efficacy of inactivated reverse-genetics-based H5N8 highly pathogenic avian influenza virus vaccine with various adjuvants via parenteral and mucosal routes in chickens
10. Intranasal monoclonal antibodies to mugwort pollen reduce allergic inflammation in a mouse model of allergic rhinitis and asthma
1